Skip to main content
Top
Published in: Current Cardiovascular Imaging Reports 1/2014

01-01-2014 | Heart Failure and Targeted Imaging (T Schindler and E Schelbert, Section Editors)

Imaging of Cardiac Autonomic Innervation with SPECT and PET

Author: Mark I. Travin

Published in: Current Cardiovascular Imaging Reports | Issue 1/2014

Login to get access

Abstract

Heart failure (HF) is a condition with high mortality and morbidity. A major component of HF pathophysiology is the body’s neurohormonal response that includes activation of the sympathetic nervous system. Imaging of cardiac sympathetic innervation with a radionuclide tracer, such as the extensively studied norepinephrine analogue 123I-meta-iodiobenzylguanidine (123I-mIBG), provides unique insights into a patient’s condition. Cardiac uptake of 123I-mIBG, measured as a heart to mediastinal ratio (H/M), has consistently been shown to correlate with poor outcome and predisposition to cardiac arrhythmias independent of conventional clinical, laboratory, and heart function parameters. 123I-mIBG imaging promises to help monitor a patient’s clinical course and response to therapy, and shows potential to improve patient selection for advanced therapies such as ICDs, LVADs, and transplant. Imaging regional abnormalities, although less studied, shows promise for more precisely identifying patients at risk for arrhythmias, and higher resolution PET tracers such as 11C-HED and 18 F-LMI1195 show potential.
Literature
1.
go back to reference Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Radionuclide Imaging). J Am Coll Cardiol. 2003;42:1318–33.PubMedCrossRef Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Radionuclide Imaging). J Am Coll Cardiol. 2003;42:1318–33.PubMedCrossRef
2.
go back to reference Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. J Nucl Cardiol. 2004;11:171–85.PubMedCrossRef Shaw LJ, Iskandrian AE. Prognostic value of gated myocardial perfusion SPECT. J Nucl Cardiol. 2004;11:171–85.PubMedCrossRef
4.
go back to reference Sinusas AJ, Thomas JD, Mills G. The future of molecular imaging. J Am Coll Cardiol Imaging. 2011;4:799–806.CrossRef Sinusas AJ, Thomas JD, Mills G. The future of molecular imaging. J Am Coll Cardiol Imaging. 2011;4:799–806.CrossRef
5.
go back to reference Roger VL, Go AS, Lloyd-Jones DM, et al. On behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation. 2012;125:e2–220.PubMedCrossRef Roger VL, Go AS, Lloyd-Jones DM, et al. On behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2012 update: a report from the American Heart Association. Circulation. 2012;125:e2–220.PubMedCrossRef
6.
go back to reference Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344–50.PubMedCrossRef Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344–50.PubMedCrossRef
7.
go back to reference Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–402.PubMedCrossRef Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–402.PubMedCrossRef
8.
go back to reference Cohn JN, Ferrari R, Sharpe N. On behalf of an international forum on cardiac remodeling. Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35:569–82.PubMedCrossRef Cohn JN, Ferrari R, Sharpe N. On behalf of an international forum on cardiac remodeling. Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35:569–82.PubMedCrossRef
9.
go back to reference Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guideline for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;119:e391–479.PubMedCrossRef Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guideline for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;119:e391–479.PubMedCrossRef
10.
go back to reference Boogers MJ, Veltman CE, Bax JJ. Cardiac autonomic nervous system in heart failure: imaging technique and clinical implications. Curr Cardiol Rev. 2011;7:35–42.CrossRef Boogers MJ, Veltman CE, Bax JJ. Cardiac autonomic nervous system in heart failure: imaging technique and clinical implications. Curr Cardiol Rev. 2011;7:35–42.CrossRef
12.
go back to reference Goldsmith SR. Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr Heart Fail Rep. 2004;1:45–50.PubMedCrossRef Goldsmith SR. Interactions between the sympathetic nervous system and the RAAS in heart failure. Curr Heart Fail Rep. 2004;1:45–50.PubMedCrossRef
13.
14.
go back to reference Thackeray JT, Bengel FM. Assessment of cardiac autonomic neuronal function using PET imaging. J Nucl Cardiol. 2013;20:150–65.PubMedCrossRef Thackeray JT, Bengel FM. Assessment of cardiac autonomic neuronal function using PET imaging. J Nucl Cardiol. 2013;20:150–65.PubMedCrossRef
15.
go back to reference Kapa S, Somers VK. Cardiovascular manifestations of autonomic disorders. In: Libby P, Bonow RO, Mann DL, Zipes DP, Braunwald E, editors. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 8th ed. Philadelphia: Saunders Elsevier; 2008. p. 2171–83. Kapa S, Somers VK. Cardiovascular manifestations of autonomic disorders. In: Libby P, Bonow RO, Mann DL, Zipes DP, Braunwald E, editors. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 8th ed. Philadelphia: Saunders Elsevier; 2008. p. 2171–83.
16.
go back to reference Zipes DP. Autonomic modulation of cardiac arrhythmias. In: Zipes DP, Jalife J, editors. Cardiac Electrophysiology: From Cell to Bedside. 2nd ed. Philadelphia: W.B. Saunders Company; 1995. p. 441–2. Zipes DP. Autonomic modulation of cardiac arrhythmias. In: Zipes DP, Jalife J, editors. Cardiac Electrophysiology: From Cell to Bedside. 2nd ed. Philadelphia: W.B. Saunders Company; 1995. p. 441–2.
17.
go back to reference Raffel DM, Wieland DM. Development of mIBG as a cardiac innervation imaging agent. J Am Coll Cardiol Imaging. 2010;3:111–6.CrossRef Raffel DM, Wieland DM. Development of mIBG as a cardiac innervation imaging agent. J Am Coll Cardiol Imaging. 2010;3:111–6.CrossRef
18.
go back to reference Wieland DM, Mangner TJ, Inbasekaran MN, et al. Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines. J Med Chem. 1984;27:149–55.PubMedCrossRef Wieland DM, Mangner TJ, Inbasekaran MN, et al. Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines. J Med Chem. 1984;27:149–55.PubMedCrossRef
19.
go back to reference Kline RC, Swanson DP, Wieland DM, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981;22:129–32.PubMed Kline RC, Swanson DP, Wieland DM, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981;22:129–32.PubMed
20.
go back to reference Travin MI. Cardiac neuronal imaging at the edge of clinical application. Cardiol Clin. 2009;27:311–27.PubMedCrossRef Travin MI. Cardiac neuronal imaging at the edge of clinical application. Cardiol Clin. 2009;27:311–27.PubMedCrossRef
21.
go back to reference Ji Sang Y, Travin MI. Radionuclide imaging of cardiac autonomic innervation. J Nucl Cardiol. 2010;17:655–66.PubMedCrossRef Ji Sang Y, Travin MI. Radionuclide imaging of cardiac autonomic innervation. J Nucl Cardiol. 2010;17:655–66.PubMedCrossRef
23.
go back to reference Sisson JC, Wieland DM. Radiolabeled meta-iodobenzylguanidine pharmacology: pharmacology and clinical studies. Am J Physiol Imaging. 1986;1:96–103.PubMed Sisson JC, Wieland DM. Radiolabeled meta-iodobenzylguanidine pharmacology: pharmacology and clinical studies. Am J Physiol Imaging. 1986;1:96–103.PubMed
24.
go back to reference Hattori N, Schwaiger M. Metaiodobenzylguanidine scintigraphy of the heart. What have we learned clinically? Eur J Nucl Med. 2000;27:1–6.PubMedCrossRef Hattori N, Schwaiger M. Metaiodobenzylguanidine scintigraphy of the heart. What have we learned clinically? Eur J Nucl Med. 2000;27:1–6.PubMedCrossRef
25.
go back to reference Flotats A, Carrió I, Agostini D, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010;37:1802–12.PubMedCrossRef Flotats A, Carrió I, Agostini D, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010;37:1802–12.PubMedCrossRef
26.
go back to reference Verberne HJ, Feenstra C, de Jong WM, et al. Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: a phantom study. Eur J Nucl Med Mol Imaging. 2005;32:1100–7.PubMedCrossRef Verberne HJ, Feenstra C, de Jong WM, et al. Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: a phantom study. Eur J Nucl Med Mol Imaging. 2005;32:1100–7.PubMedCrossRef
27.
go back to reference Chen J, Garcia EV, Galt JR, et al. Optimized acquisition and processing protocols for I-123 cardiac SPECT imaging. J Nucl Cardiol. 2006;13:251–60.PubMed Chen J, Garcia EV, Galt JR, et al. Optimized acquisition and processing protocols for I-123 cardiac SPECT imaging. J Nucl Cardiol. 2006;13:251–60.PubMed
28.
go back to reference Agostini D, Belin A, Amar MH, et al. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: a 123I-MIBG scintigraphic study. J Nucl Med. 2000;41:845–51.PubMed Agostini D, Belin A, Amar MH, et al. Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: a 123I-MIBG scintigraphic study. J Nucl Med. 2000;41:845–51.PubMed
29.
go back to reference Yamada T, Shimonagata T, Fukunami M, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure. J Am Coll Cardiol. 2003;41:231–8.PubMedCrossRef Yamada T, Shimonagata T, Fukunami M, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure. J Am Coll Cardiol. 2003;41:231–8.PubMedCrossRef
30.
go back to reference Gerson MC, Craft LL, McGuire N, et al. Carvedilol improves left ventricular function in heart failure with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine. J Nucl Cardiol. 2002;9:608–15.PubMedCrossRef Gerson MC, Craft LL, McGuire N, et al. Carvedilol improves left ventricular function in heart failure with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine. J Nucl Cardiol. 2002;9:608–15.PubMedCrossRef
31.
go back to reference Veltman CE, Boogers MJ, Meinardi JE, et al. Reproducibility of planar (123) I-meta-iodobenzylguanidine MIBG) myocardial scintigraphy in patients with heart failure. Eur J Nucl Med Mol Imaging. 2012;39:1599–608.PubMedCrossRefPubMedCentral Veltman CE, Boogers MJ, Meinardi JE, et al. Reproducibility of planar (123) I-meta-iodobenzylguanidine MIBG) myocardial scintigraphy in patients with heart failure. Eur J Nucl Med Mol Imaging. 2012;39:1599–608.PubMedCrossRefPubMedCentral
32.
go back to reference Okuda K, Nakajima K, Hosoya T, et al. Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac Iodine-123 MIBG imaging. J Nucl Cardiol. 2011;18:82–9.PubMedCrossRef Okuda K, Nakajima K, Hosoya T, et al. Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac Iodine-123 MIBG imaging. J Nucl Cardiol. 2011;18:82–9.PubMedCrossRef
33.
go back to reference Jacobson AF, Lombard J, Banerjee G, Camici PG. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multi-center international trials. J Nucl Cardiol. 2009;16:113–21.PubMedCrossRef Jacobson AF, Lombard J, Banerjee G, Camici PG. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multi-center international trials. J Nucl Cardiol. 2009;16:113–21.PubMedCrossRef
34.
go back to reference Chen GP, Tabibiazar R, Branch KR, et al. Cardiac receptor physiology and imaging: an update. J Nucl Cardiol. 2005;12:714–30.PubMedCrossRef Chen GP, Tabibiazar R, Branch KR, et al. Cardiac receptor physiology and imaging: an update. J Nucl Cardiol. 2005;12:714–30.PubMedCrossRef
35.
go back to reference Morozumi T, Kusuoka H, Fukuchi K, et al. Myocardial iodine-123-metaiodobenzylguanidine images and autonomic nerve activity in normal subjects. J Nucl Med. 1997;38:49–52.PubMed Morozumi T, Kusuoka H, Fukuchi K, et al. Myocardial iodine-123-metaiodobenzylguanidine images and autonomic nerve activity in normal subjects. J Nucl Med. 1997;38:49–52.PubMed
36.
go back to reference Minardo JD, Tuli MM, Mock BH, et al. Scintigraphic and electrophysiologic evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation. 1988;78:1008–19.PubMedCrossRef Minardo JD, Tuli MM, Mock BH, et al. Scintigraphic and electrophysiologic evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation. 1988;78:1008–19.PubMedCrossRef
37.
go back to reference Bax JJ, Kraft O, Buxton AE, et al. 123I-mIBG Scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: a prospective multi-center pilot study. Circ Cardiovasc Img. 2008;1:131–40.CrossRef Bax JJ, Kraft O, Buxton AE, et al. 123I-mIBG Scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: a prospective multi-center pilot study. Circ Cardiovasc Img. 2008;1:131–40.CrossRef
38.
go back to reference Tsuchimochi S, Tamaki N, Tadamura E, et al. Age and gender differences in normal myocardial adrenergic neuronal function evaluated by iodine-123-MIBG imaging. J Nucl Med. 1995;36:969–74.PubMed Tsuchimochi S, Tamaki N, Tadamura E, et al. Age and gender differences in normal myocardial adrenergic neuronal function evaluated by iodine-123-MIBG imaging. J Nucl Med. 1995;36:969–74.PubMed
39.
go back to reference Somsen GA, Verberne HJ, Fleury E, Righetti A. Normal values and within-subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: implications for clinical studies. J Nucl Cardiol. 2004;11:126–33.PubMedCrossRef Somsen GA, Verberne HJ, Fleury E, Righetti A. Normal values and within-subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: implications for clinical studies. J Nucl Cardiol. 2004;11:126–33.PubMedCrossRef
40.
go back to reference Estorch M, Serra-Grima R, Flotats A, et al. Myocardial sympathetic innervation in the athlete’s sinus bradycardia. Is there selective inferior myocardial wall denervation? J Nucl Cardiol. 2000;7:354–8.PubMedCrossRef Estorch M, Serra-Grima R, Flotats A, et al. Myocardial sympathetic innervation in the athlete’s sinus bradycardia. Is there selective inferior myocardial wall denervation? J Nucl Cardiol. 2000;7:354–8.PubMedCrossRef
41.
go back to reference Bulow HP, Stahl F, Lauer B, et al. Alterations of myocardial presynaptic sympathetic innervation in patients with multi-vessel coronary artery disease but without history of myocardial infarction. Nucl Med Commun. 2003;24:233–9.PubMedCrossRef Bulow HP, Stahl F, Lauer B, et al. Alterations of myocardial presynaptic sympathetic innervation in patients with multi-vessel coronary artery disease but without history of myocardial infarction. Nucl Med Commun. 2003;24:233–9.PubMedCrossRef
42.
go back to reference Matsunari I, Schricke U, Bengel FM, et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation. 2000;101:2579–85.PubMedCrossRef Matsunari I, Schricke U, Bengel FM, et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation. 2000;101:2579–85.PubMedCrossRef
43.
go back to reference Tomoda H, Yoshioka K, Shiina Y, et al. Regional sympathetic denervation detected by iodine 123 metaiodobenzylguanidine in non-Q-wave myocardial infarction and unstable angina. Am Heart J. 1994;128:452–8.PubMedCrossRef Tomoda H, Yoshioka K, Shiina Y, et al. Regional sympathetic denervation detected by iodine 123 metaiodobenzylguanidine in non-Q-wave myocardial infarction and unstable angina. Am Heart J. 1994;128:452–8.PubMedCrossRef
44.
go back to reference Watanabe K, Takahashi T, Miyajima S, et al. Myocardial sympathetic denervation, fatty acid metabolism, and left ventricular wall motion in vasospastic angina. J Nucl Med. 2002;43:1476–81.PubMed Watanabe K, Takahashi T, Miyajima S, et al. Myocardial sympathetic denervation, fatty acid metabolism, and left ventricular wall motion in vasospastic angina. J Nucl Med. 2002;43:1476–81.PubMed
45.
go back to reference Stanton MS, Tuli MM, Radtke NL, et al. Regional sympathetic denervation after MI in humans detected noninvasively using I-123-MIBG. J Am Coll Cardiol. 1989;14:1519–26.PubMedCrossRef Stanton MS, Tuli MM, Radtke NL, et al. Regional sympathetic denervation after MI in humans detected noninvasively using I-123-MIBG. J Am Coll Cardiol. 1989;14:1519–26.PubMedCrossRef
46.
go back to reference McGhie AI, Corbett JR, Akers MS, et al. Regional cardiac adrenergic function using I-123 MIBG SPECT imaging after acute myocardial infarction. Am J Cardiol. 1991;67:236–42.PubMedCrossRef McGhie AI, Corbett JR, Akers MS, et al. Regional cardiac adrenergic function using I-123 MIBG SPECT imaging after acute myocardial infarction. Am J Cardiol. 1991;67:236–42.PubMedCrossRef
47.
go back to reference Stevens MJ, Raffel DM, Allman KC, et al. Cardiac sympathetic dysinnervation in diabetes. Implications for enhanced cardiovascular risk. Circulation. 1998;98:961–8.PubMedCrossRef Stevens MJ, Raffel DM, Allman KC, et al. Cardiac sympathetic dysinnervation in diabetes. Implications for enhanced cardiovascular risk. Circulation. 1998;98:961–8.PubMedCrossRef
48.
go back to reference Nagamachi S, Fujita S, Nishii R, et al. Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with noninsulin-dependent diabetes mellitus. J Nucl Cardiol. 2006;13:34–42.PubMedCrossRef Nagamachi S, Fujita S, Nishii R, et al. Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with noninsulin-dependent diabetes mellitus. J Nucl Cardiol. 2006;13:34–42.PubMedCrossRef
49.
go back to reference Schofer J, Spielmann R, Schuchert A, et al. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1988;12:1252–8.PubMedCrossRef Schofer J, Spielmann R, Schuchert A, et al. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1988;12:1252–8.PubMedCrossRef
50.
go back to reference Merlet P, Valette H, Dubois-Randé J, et al. Prognostic value of cardiac metaiodobenzylguanidine in patients with heart failure. J Nucl Med. 1992;33:471–7.PubMed Merlet P, Valette H, Dubois-Randé J, et al. Prognostic value of cardiac metaiodobenzylguanidine in patients with heart failure. J Nucl Med. 1992;33:471–7.PubMed
51.
go back to reference Nakata T, Miyamoto K, Doi A, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol. 1998;5:579–90.PubMedCrossRef Nakata T, Miyamoto K, Doi A, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol. 1998;5:579–90.PubMedCrossRef
52.
go back to reference Ogita H, Shimonagata T, Fukunami M, et al. Prognostic significance of cardiac 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart. 2001;86:656–60.PubMedCrossRef Ogita H, Shimonagata T, Fukunami M, et al. Prognostic significance of cardiac 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart. 2001;86:656–60.PubMedCrossRef
53.
go back to reference Kioka H, Yamada T, Mine T, et al. Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging. Heart. 2007;93:1213–8.PubMedCrossRef Kioka H, Yamada T, Mine T, et al. Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging. Heart. 2007;93:1213–8.PubMedCrossRef
54.
go back to reference Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29:1147–59.PubMedCrossRef Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29:1147–59.PubMedCrossRef
55.
go back to reference Agostini D, Verberne HJ, Burchert W, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multi-center study. Eur J Nucl Med Mol Img. 2008;35:535–46.CrossRef Agostini D, Verberne HJ, Burchert W, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multi-center study. Eur J Nucl Med Mol Img. 2008;35:535–46.CrossRef
56.
go back to reference •• Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55:2212–21. To date the only large, prospective, multi-center study examing the clinical utility of 123 I-mIBG imaging in patients with heart failure..PubMedCrossRef •• Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55:2212–21. To date the only large, prospective, multi-center study examing the clinical utility of 123 I-mIBG imaging in patients with heart failure..PubMedCrossRef
57.
go back to reference Chirumamilla A, Travin MI. Cardiac applications of 123I-mIBG imaging. Semin Nucl Med. 2011;41:374–87.PubMedCrossRef Chirumamilla A, Travin MI. Cardiac applications of 123I-mIBG imaging. Semin Nucl Med. 2011;41:374–87.PubMedCrossRef
58.
go back to reference Travin M, Anathassubramaniam K, Henzlova MJ, et al. Imaging of myocardial sympathetic innervation for prediction of cardiac and all-cause mortality in heart failure: analysis from the ADMIRE-HF trial. Circulation. 2009;120:S350. Travin M, Anathassubramaniam K, Henzlova MJ, et al. Imaging of myocardial sympathetic innervation for prediction of cardiac and all-cause mortality in heart failure: analysis from the ADMIRE-HF trial. Circulation. 2009;120:S350.
59.
go back to reference •• Nakata T, Nakajima K, Yamashina S, et al. A pooled analysis of multi-center cohort studies of I-123-mIBG cardiac sympathetic innervation imaging for assessment of long-term prognosis in chronic heart failure. J Am Coll Cardiol Imaging. 2013;6:772–84. A combined analysis of previous prospectively acquired data in 6 individual Japanese medical centers that confirms and expands the findings of ADMIRE-HF..CrossRef •• Nakata T, Nakajima K, Yamashina S, et al. A pooled analysis of multi-center cohort studies of I-123-mIBG cardiac sympathetic innervation imaging for assessment of long-term prognosis in chronic heart failure. J Am Coll Cardiol Imaging. 2013;6:772–84. A combined analysis of previous prospectively acquired data in 6 individual Japanese medical centers that confirms and expands the findings of ADMIRE-HF..CrossRef
60.
go back to reference Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model. Prediction of survival in heart failure. Circulation. 2006;113:1424–33.PubMedCrossRef Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model. Prediction of survival in heart failure. Circulation. 2006;113:1424–33.PubMedCrossRef
61.
go back to reference Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.PubMedCrossRef Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.PubMedCrossRef
62.
go back to reference •• Ketchum ES, Jacobson AF, Caldwell JH, et al. Selective improvement in Seattle heart failure model risk stratification using iodine-123 meta-iodobenzylguanidine imaging. J Nucl Cardiol. 2012;19:1007–16. A sophisticated analysis of ADMIRE-HF data showing the incremental risk stratification value of 123 I-mIBG imaging beyond the comprehensive Seattle Heart Failure model..PubMedCrossRef •• Ketchum ES, Jacobson AF, Caldwell JH, et al. Selective improvement in Seattle heart failure model risk stratification using iodine-123 meta-iodobenzylguanidine imaging. J Nucl Cardiol. 2012;19:1007–16. A sophisticated analysis of ADMIRE-HF data showing the incremental risk stratification value of 123 I-mIBG imaging beyond the comprehensive Seattle Heart Failure model..PubMedCrossRef
63.
go back to reference Shaw LJ, Min JK, Hachamovitch R, et al. Cardiovascular imaging research at the crossroads. JACC Cardiovasc Imaging. 2010;3:316–24.PubMedCrossRef Shaw LJ, Min JK, Hachamovitch R, et al. Cardiovascular imaging research at the crossroads. JACC Cardiovasc Imaging. 2010;3:316–24.PubMedCrossRef
64.
go back to reference Waqar F, Dunlap SH, Gerson MC. What will be the role of I-123 MIBG in improving the outcome of medically treated heart failure patients? J Nucl Cardiol. 2012;19:1198–205.PubMedCrossRef Waqar F, Dunlap SH, Gerson MC. What will be the role of I-123 MIBG in improving the outcome of medically treated heart failure patients? J Nucl Cardiol. 2012;19:1198–205.PubMedCrossRef
65.
go back to reference Treglia G, Stefanelli I, Giordano BA. Clinical usefulness of myocardial innervation imaging using Iodine-123-meta-iodobenzylguanidine scintigraphy in evaluating the effectiveness of pharmacological treatments in patients with heart failure: an overview. Eur Rev Med Pharmacol Sci. 2013;17:56–8.PubMed Treglia G, Stefanelli I, Giordano BA. Clinical usefulness of myocardial innervation imaging using Iodine-123-meta-iodobenzylguanidine scintigraphy in evaluating the effectiveness of pharmacological treatments in patients with heart failure: an overview. Eur Rev Med Pharmacol Sci. 2013;17:56–8.PubMed
66.
go back to reference Cohen-Solal A, Rouzet F, Berdeaux A, et al. Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure. J Nucl Med. 2005;46:1796–803.PubMed Cohen-Solal A, Rouzet F, Berdeaux A, et al. Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure. J Nucl Med. 2005;46:1796–803.PubMed
67.
go back to reference Choi JY, Lee KH, Hong KP, et al. Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. J Nucl Cardiol. 2001;8:4–9.PubMedCrossRef Choi JY, Lee KH, Hong KP, et al. Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. J Nucl Cardiol. 2001;8:4–9.PubMedCrossRef
68.
go back to reference Suwa M, Otake Y, Moriguchi A, et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to β-blocker therapy in patients with dilated cardiomyopathy. Am Heart J. 1997;133:353–8.PubMedCrossRef Suwa M, Otake Y, Moriguchi A, et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to β-blocker therapy in patients with dilated cardiomyopathy. Am Heart J. 1997;133:353–8.PubMedCrossRef
69.
go back to reference Matsui T, Tsutamoto T, Maeda K, et al. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments – comparison with neurohumoral factors. Circ J. 2002;66:537–43.PubMedCrossRef Matsui T, Tsutamoto T, Maeda K, et al. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments – comparison with neurohumoral factors. Circ J. 2002;66:537–43.PubMedCrossRef
70.
go back to reference • Drakos SG, Athanasoulis T, Malliaras KG, et al. Myocardial sympathetic innervation and long-term left ventricular mechanical unloading. J Am Coll Cardiol Imaging. 2010;3:64–70. A small study, but shows that 123 I-mIBG imaging may help manage use of LVADs in patients with advanced heart failure. CrossRef • Drakos SG, Athanasoulis T, Malliaras KG, et al. Myocardial sympathetic innervation and long-term left ventricular mechanical unloading. J Am Coll Cardiol Imaging. 2010;3:64–70. A small study, but shows that 123 I-mIBG imaging may help manage use of LVADs in patients with advanced heart failure. CrossRef
71.
go back to reference George RS, Birks EJ, Cheetham A, et al. The effect of long-term left ventricular assist device support on myocardial sympathetic activity in patients with nonischaemic dilated cardiomyopathy. Eur J Heart Fail. 2013;15:1035–43. George RS, Birks EJ, Cheetham A, et al. The effect of long-term left ventricular assist device support on myocardial sympathetic activity in patients with nonischaemic dilated cardiomyopathy. Eur J Heart Fail. 2013;15:1035–43.
72.
go back to reference Jessup M, Abraham WT, Casey DE, et al. Writing on behalf of the 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult Writing Committee. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;53:1343–82.CrossRef Jessup M, Abraham WT, Casey DE, et al. Writing on behalf of the 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult Writing Committee. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;53:1343–82.CrossRef
73.
go back to reference Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.PubMedCrossRef Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.PubMedCrossRef
74.
go back to reference Fisher JD, Ector HE. Relative and absolute benefits: main results should be reported in absolute terms. Pacing Clin Electrophysiol. 2007;30:935–7.PubMedCrossRef Fisher JD, Ector HE. Relative and absolute benefits: main results should be reported in absolute terms. Pacing Clin Electrophysiol. 2007;30:935–7.PubMedCrossRef
75.
go back to reference Lee DS, Krahn AD, Healey JS, et al. Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol. 2010;55:774–82.PubMedCrossRef Lee DS, Krahn AD, Healey JS, et al. Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol. 2010;55:774–82.PubMedCrossRef
76.
go back to reference Buxton AE, Lee KL, Hafley GE, et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol. 2007;50:1150–7.PubMedCrossRef Buxton AE, Lee KL, Hafley GE, et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol. 2007;50:1150–7.PubMedCrossRef
77.
go back to reference Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, et al. Out-of-hospital cardiac arrest–the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J. 2003;24:1204–9.PubMedCrossRef Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, et al. Out-of-hospital cardiac arrest–the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J. 2003;24:1204–9.PubMedCrossRef
78.
go back to reference Stecker EC, Vickers C, Waltz J, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol. 2006;47:1161–6.PubMedCrossRef Stecker EC, Vickers C, Waltz J, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol. 2006;47:1161–6.PubMedCrossRef
79.
go back to reference Myerburg RJ. Implantable cardioverter-defibrillators after myocardial infarction. N Engl J Med. 2008;359:2245–53.PubMedCrossRef Myerburg RJ. Implantable cardioverter-defibrillators after myocardial infarction. N Engl J Med. 2008;359:2245–53.PubMedCrossRef
81.
go back to reference Passman R, Kadish A. Shouldn't everyone have an implantable cardioverter-defibrillator? Circulation. 2009;120:2166–7.PubMedCrossRef Passman R, Kadish A. Shouldn't everyone have an implantable cardioverter-defibrillator? Circulation. 2009;120:2166–7.PubMedCrossRef
82.
83.
go back to reference • Gerson MC, Abdallah M, Muth JN, Costea AI. Will imaging assist in the selection of patients with heart failure for an ICD? JACC Cardiovasc Imaging. 2010;3:101–10. An excellent discussion of potential use of cardiac autonomic imaging to select patients most likely to benefit from ICD implantation..PubMedCrossRef • Gerson MC, Abdallah M, Muth JN, Costea AI. Will imaging assist in the selection of patients with heart failure for an ICD? JACC Cardiovasc Imaging. 2010;3:101–10. An excellent discussion of potential use of cardiac autonomic imaging to select patients most likely to benefit from ICD implantation..PubMedCrossRef
84.
go back to reference Arora R, Ferrick KJ, Nakata T, et al. I-123 MIBG imaging and heart rate variability analysis to predict the needs for an implantable cardioverter defibrillator. J Nucl Cardiol. 2003;10:121–31.PubMedCrossRef Arora R, Ferrick KJ, Nakata T, et al. I-123 MIBG imaging and heart rate variability analysis to predict the needs for an implantable cardioverter defibrillator. J Nucl Cardiol. 2003;10:121–31.PubMedCrossRef
85.
go back to reference Nagahara D, Nakata T, Hashimoto A, et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med. 2008;49:225–33.PubMedCrossRef Nagahara D, Nakata T, Hashimoto A, et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med. 2008;49:225–33.PubMedCrossRef
86.
go back to reference Nishisato K, Hashimoto A, Nakata T, et al. Impaired cardiac sympathetic innervation and myocardial perfusion are related to lethal arrhythmia: quantification of cardiac tracers in patients with ICDs. J Nucl Med. 2010;51:1241–9.PubMedCrossRef Nishisato K, Hashimoto A, Nakata T, et al. Impaired cardiac sympathetic innervation and myocardial perfusion are related to lethal arrhythmia: quantification of cardiac tracers in patients with ICDs. J Nucl Med. 2010;51:1241–9.PubMedCrossRef
87.
go back to reference Kasama S, Toyama T, Sumino H, et al. Prognostic value of serial cardiac 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction. J Nucl Med. 2008;49:907–14.PubMedCrossRef Kasama S, Toyama T, Sumino H, et al. Prognostic value of serial cardiac 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction. J Nucl Med. 2008;49:907–14.PubMedCrossRef
88.
go back to reference • Tamaki S, Yamada T, Okuyama Y, et al. Cardiac iodine-123 Metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol. 2009;53:426–35. Reports that 123 I-mIBG imaging predicts sudden cardiac death better than various sophisticated ECG analyses..PubMedCrossRef • Tamaki S, Yamada T, Okuyama Y, et al. Cardiac iodine-123 Metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol. 2009;53:426–35. Reports that 123 I-mIBG imaging predicts sudden cardiac death better than various sophisticated ECG analyses..PubMedCrossRef
89.
go back to reference • Boogers MJ, Borleffs CJ, Henneman MM, et al. Cardiac sympathetic denervation assessed with 123-Iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol. 2010;55:2769–77. Demonstrates how SPECT 123 I-mIBG imaging might be used to risk-stratify patients in terms of deciding who is likely to benefit from ICD implantation..PubMedCrossRef • Boogers MJ, Borleffs CJ, Henneman MM, et al. Cardiac sympathetic denervation assessed with 123-Iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol. 2010;55:2769–77. Demonstrates how SPECT 123 I-mIBG imaging might be used to risk-stratify patients in terms of deciding who is likely to benefit from ICD implantation..PubMedCrossRef
90.
go back to reference Exner DV, Klein GJ, Prystowsky EN. Primary prevention of sudden death with implantable defibrillator therapy in patients with cardiac disease: can we afford to do it? (Can we afford not to?). Circulation. 2001;104:1564–70.PubMedCrossRef Exner DV, Klein GJ, Prystowsky EN. Primary prevention of sudden death with implantable defibrillator therapy in patients with cardiac disease: can we afford to do it? (Can we afford not to?). Circulation. 2001;104:1564–70.PubMedCrossRef
91.
go back to reference • Shah AM, Bourgoun M, Narula J, et al. Influence of ejection fraction on the prognostic value of sympathetic innervation imaging with Iodine-123 MIBG in heart failure. J Am Coll Cardiol Imaging. 2012;5:1139–46. Shows that 123 I-mIBG imaging may also be useful in heart failure patients with higher ejection fractions..CrossRef • Shah AM, Bourgoun M, Narula J, et al. Influence of ejection fraction on the prognostic value of sympathetic innervation imaging with Iodine-123 MIBG in heart failure. J Am Coll Cardiol Imaging. 2012;5:1139–46. Shows that 123 I-mIBG imaging may also be useful in heart failure patients with higher ejection fractions..CrossRef
92.
go back to reference Luisi Jr AJ, Suzuki G, Dekemp R, et al. Regional 11C-Hydroxyephedrine retention in hibernating myocardium: chronic inhomogeneity of sympathetic innervation in the absence of infarction. J Nucl Med. 2005;46:1368–74.PubMed Luisi Jr AJ, Suzuki G, Dekemp R, et al. Regional 11C-Hydroxyephedrine retention in hibernating myocardium: chronic inhomogeneity of sympathetic innervation in the absence of infarction. J Nucl Med. 2005;46:1368–74.PubMed
93.
go back to reference Yu M, Bozek J, Lamoy M, et al. Evaluation of LMI 1195, a novel 18 F-labeled cardiac neuronal PET imaging agent, in cells and animal models. Circ Cardiovasc Imaging. 2011;4:435–43.PubMedCrossRef Yu M, Bozek J, Lamoy M, et al. Evaluation of LMI 1195, a novel 18 F-labeled cardiac neuronal PET imaging agent, in cells and animal models. Circ Cardiovasc Imaging. 2011;4:435–43.PubMedCrossRef
94.
go back to reference Odaka K, von Scheidt W, Ziegler S, et al. Reappearance of cardiac presynaptic nerve terminals in the transplanted heart: correlation between PET using (11) C-hydroxyephedrine and invasively measured norepinephrine release. J Nucl Med. 2001;42:1011–6.PubMed Odaka K, von Scheidt W, Ziegler S, et al. Reappearance of cardiac presynaptic nerve terminals in the transplanted heart: correlation between PET using (11) C-hydroxyephedrine and invasively measured norepinephrine release. J Nucl Med. 2001;42:1011–6.PubMed
95.
go back to reference Wichter T, Matheja P, Eckardt L, et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation. 2002;105:702–6.PubMedCrossRef Wichter T, Matheja P, Eckardt L, et al. Cardiac autonomic dysfunction in Brugada syndrome. Circulation. 2002;105:702–6.PubMedCrossRef
96.
go back to reference Schäfers M, Lerch H, Wichter T, et al. Cardiac sympathetic innervation in patients with idiopathic right ventricular outflow tract tachycardia. J Am Coll Cardiol. 1998;32:181–6.PubMedCrossRef Schäfers M, Lerch H, Wichter T, et al. Cardiac sympathetic innervation in patients with idiopathic right ventricular outflow tract tachycardia. J Am Coll Cardiol. 1998;32:181–6.PubMedCrossRef
97.
go back to reference • Fallavollita JA, Canty JM. Dysinnervated but viable myocardium in ischemic heart disease. J Nucl Cardiol. 2010;17:1107–15. An excellent review describing the use autonomic imaging with PET tracers in ischemic heart disease..PubMedCrossRefPubMedCentral • Fallavollita JA, Canty JM. Dysinnervated but viable myocardium in ischemic heart disease. J Nucl Cardiol. 2010;17:1107–15. An excellent review describing the use autonomic imaging with PET tracers in ischemic heart disease..PubMedCrossRefPubMedCentral
98.
go back to reference Fallavollita JA, Luisi Jr AJ, Michalek SM, et al. Prediction of arrhythmic events with positron emission tomography: PAREPET study design and methods. Contemp Clin Trials. 2006;27:374–88.PubMedCrossRef Fallavollita JA, Luisi Jr AJ, Michalek SM, et al. Prediction of arrhythmic events with positron emission tomography: PAREPET study design and methods. Contemp Clin Trials. 2006;27:374–88.PubMedCrossRef
99.
go back to reference Fallavollita JA, Heavey BM, Luisi Jr AJ, et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol. 2013. doi:10.1016/j.jacc.2013.07.096. Fallavollita JA, Heavey BM, Luisi Jr AJ, et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol. 2013. doi:10.​1016/​j.​jacc.​2013.​07.​096.
Metadata
Title
Imaging of Cardiac Autonomic Innervation with SPECT and PET
Author
Mark I. Travin
Publication date
01-01-2014
Publisher
Springer US
Published in
Current Cardiovascular Imaging Reports / Issue 1/2014
Print ISSN: 1941-9066
Electronic ISSN: 1941-9074
DOI
https://doi.org/10.1007/s12410-013-9242-0

Other articles of this Issue 1/2014

Current Cardiovascular Imaging Reports 1/2014 Go to the issue

Heart Failure and Targeted Imaging (T. Schindler and E. Schelbert, Section Editors)

Recent Developments in Imaging of Myocardial Angiotensin Receptors

Heart Failure and Targeted Imaging (T. Schindler and E. Schelbert, Section Editors)

What You See is What You Get? Imaging of Cell Therapy for Cardiac Regeneration

Heart Failure and Targeted Imaging (T Schindler and E Schelbert, Section Editors)

Imaging of Myocardial Oxidative Metabolism in Heart Failure